GSK wins Hibsago approval as Jefferies backs GSK stock

Published on 10/23/2026 at 09:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jefferies kept a Buy rating and a GBp 2,500 target on October 21, 2026. GSK stock costs EUR 22.61 before results on October 28, 2026.

Hibsago strengthens GSK pipeline

GSK secured US approval for Hibsago on October 21, 2026, after a 19 percent functional cure rate in late-stage studies.
Jefferies retained its Buy rating and GBp 2,500 price target on October 21, 2026.
GSK stock traded at EUR 22.61 at 9:43 a.m. CEST at Lang & Schwarz on October 23, 2026.
GSK is expected to report third-quarter 2026 results on October 28, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) was trading at EUR 22.61 at Lang & Schwarz on October 23, 2026 at 9:43 a.m. CEST. The company received US approval for Hibsago on October 21, 2026, while Jefferies retained a Buy rating and a GBp 2,500 price target.

Hibsago adds a commercial test

Hibsago, also known as bepirovirsen, was approved for eligible adults with chronic hepatitis B who do not have cirrhosis and are receiving existing antiviral therapy. Yahoo Finance reported that the treatment is designed to deliver a functional cure, supported by GSK phase III B-Well results.

The clinical signal gives the approval a measurable commercial angle. Yahoo Finance reported that Jefferies sees peak annual Hibsago sales of GBP 2.2 billion and kept its GBp 2,500 target. The analysts said execution and commercial uptake now matter more than clinical and regulatory risk.

Three recent catalysts

On October 19, 2026, GSK reported early lung cancer data showing a 61 percent confirmed response rate for risvutatug rezetecan at the 8 mg/kg dose, according to FinanzNachrichten. On October 20, 2026, US regulators approved Jemperli for adults with locally advanced rectal cancer, as reported by FinanzNachrichten. Hibsago followed on October 21, 2026.

When do results arrive?

MarketBeat said GSK is expected to report third-quarter 2026 results on October 28, 2026. The preview puts consensus revenue at USD 11.74 billion and earnings at USD 1.33 per share.

GSK stock after the approval

The next test is whether Hibsago can convert a 19 percent functional cure rate into broad treatment adoption while GSK advances its oncology and respiratory pipeline.

GSK stock was trading at EUR 22.61 at Lang & Schwarz on October 23, 2026 at 9:43 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of GSK stock.